Teveten Plus: Indications, Dosage, Precautions, Adverse Effects
Россия
  • Россия
  • Украина

Teveten Plus - Product Information

Manufacture: Abbott
Country: Australia
Condition: High Blood Pressure (Hypertension)
Class: Angiotensin receptor blockers
Form: Tablets
Ingredients: Eprosartan mesylate, hydrochlorothiazide, microcrystalline cellulose, lactose, starch–pregelatinised maize, crospovidone, magnesium stearate and Opadry 85F27320.

Name of the Medicine

Non-Proprietary Name

Eprosartan mesylate and hydrochlorothiazide

Chemical Structure

Eprosartan mesylate has a molecular weight (MW) of 520.6 and may be represented structurally as:

Hydrochlorothiazide has a molecular weight (MW) of 297.73 and maybe represented structurally as:

CAS Number(s)

Eprosartan mesylate: 144143-96-4

Hydrochlorothiazide: 58-93-5

Description

Eprosartan

Chemical name: (E)-a-[[2-butyl-1-[(4-carboxyphenyl) methyl]-1H-imidazol-5- yl]methylene]-2-thiophenepropanoic acid, monomethanesulphonate. Eprosartan mesylate is a white to off-white powder with a melting point range of 248°C to 250°C and at room temperature has a solubility of 0.91 mg/mL in water at a pH of 7.

Hydrochlorothiazide

Chemical name: 6-chloro-3, 4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1- di-oxide. Hydrochlorothiazide is a white to off white crystalline powder. It is slightly soluble in water, soluble in acetone and freely soluble in alkali hydroxides.

Teveten Plus tablets contain eprosartan mesylate equivalent to eprosartan 600 mg and 12.5 mg hydrochlorothiazide as the active ingredients. The tablets also contain the following excipients: microcrystalline cellulose, lactose, starch–pregelatinised maize, crospovidone, magnesium stearate and Opadry 85F27320.

Pharmacology

Eprosartan

Eprosartan is a potent angiotensin II receptor antagonist, which selectively binds to the AT1 receptor. Angiotensin II is a potent vasoconstrictor, and the primary active hormone of the renin-angiotensin-aldosterone system, playing a major part in the pathophysiology of hypertension. Angiotensin II binds to AT1 receptors in many tissues (e.g. vascular smooth muscle, kidney adrenal glands and heart) and produces biological effects such as vasoconstriction, sodium retention and release of aldosterone. In addition, in animals eprosartan has been shown to block the direct vasoconstrictor response to angiotensin as well as the indirect effects mediated by enhanced neurotransmission, indicating the potential to antagonise overactivity of the sympathetic nervous system.

Eprosartan blocks the binding of angiotensin II to the AT1 receptors, which prevents vasoconstriction, thus lowering blood pressure and aldosterone secretion.

Eprosartan does not compromise renal autoregulatory mechanisms. In normal adult males eprosartan has been shown to increase mean effective renal plasma flow. Eprosartan does not reduce glomerular filtration rate in normal males, in patients with hypertension or in patients with varying degrees of renal insufficiency. Eprosartan has a natriuretic effect in normal subjects on a salt restricted diet.

Eprosartan does not significantly affect urinary uric acid excretion and does not potentiate effects related to bradykinin eg. Angiotensin Converting Enzyme (ACE), mediated cough.

Hydrochlorothiazide

Hydrochlorothiazide is a thiazide with diuretic, natriuretic and antihypertensive effects. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of fluid, sodium and chloride in approximately equivalent amounts.

The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium.

The antihypertensive action of hydrochlorothiazide appears to be due to a combined diuretic effect and reduction of vascular resistance.

Pharmacokinetics

Absorption

The absolute bioavailability of eprosartan has been shown to be approximately 13% when administered alone. The bioavailability of eprosartan was increased by approximately 20% when administered with hydrochlorothiazide. This increase is not considered to be of clinical consequence. The absolute bioavailability of hydrochlorothiazide is reported to be 50–80% when administered alone. When administered concurrently with eprosartan the bioavailability decreased by approximately 20%. This decrease is not considered to be of clinical consequence. Peak plasma concentrations of eprosartan and hydrochlorothiazide occurred 0.5–4 hours and 1–4 hours, respectively, after a fasting oral dose when administered in combination. Administration of eprosartan plus hydrochlorothiazide with food does not alter the bioavailability of the hydrochlorothiazide component. Food decreases the rate of absorption of the eprosartan component, leading to a 40% decrease in the peak plasma concentration of eprosartan. The extent of absorption of the eprosartan component is reduced by approximately 10%. These changes are unlikely to be clinically significant.

Distribution

Eprosartan is highly bound to plasma proteins (approximately 98%). The extent of plasma protein binding is not influenced by gender, age, hepatic dysfunction or mild- moderate renal impairment, but has been shown to decrease in a small number of patients with severe renal impairment. The volume of distribution of eprosartan is approximately 0.22 L/kg. Hydrochlorothiazide is approximately 68% bound to plasma proteins. The volume of distribution of hydrochlorothiazide is 0.83 to 1.41 L/kg.

Metabolism

There are no active metabolites following oral and intravenous dosing with [14C] eprosartan in human subjects. Eprosartan was the only drug-related compound found in the plasma and faeces. Hydrochlorothiazide is not metabolised.

Excretion

Following intravenous [14C] eprosartan, about 61% is recovered in the faeces and about 37% in the urine. Following an oral dose of [14C] eprosartan, about 90% is recovered in the faeces and about 7% in the urine. Approximately 20% of the radioactivity excreted in the urine was an acyl glucuronide of eprosartan with the remaining 80% being unchanged eprosartan. Hydrochlorothiazide is eliminated rapidly via the kidneys.

Special Populations

There was no difference between the pharmacokinetics of men and women following a single oral dose of eprosartan.

In the elderly, eprosartan AUC and Cmax values (on average) increased approximately 2 fold, compared with young subjects.

In patients with hepatic impairment, AUC (but not Cmax) values of eprosartan are on average increased approximately 40%.

In patients with moderate renal impairment (creatinine clearance 30-59 mL/min), AUC and Cmax values are approximately 30% higher than in subjects with normal renal function. In severe renal impairment (creatinine clearance 5-29 mL/min), AUC and Cmax values are approximately 50% higher than normal (see Precautions and Dosage and Administration sections).

Clinical Trials

The efficacy and safety of eprosartan plus hydrochlorothiazide have been studied in patients with mild to moderate hypertension.

In a 2x2 factorial study with 116–122 hypertensive patients per arm, reductions in systolic and diastolic blood pressure were significantly greater with once-daily eprosartan plus hydrochlorothiazide than with the individual components. The mean placebo subtracted reduction in systolic/diastolic blood pressure after 8 weeks was 3.5/1.8 mmHg on eprosartan 600 mg, 5.5/1.5 mmHg on hydrochlorothiazide and 9.3/4.5 mmHg on the combination eprosartan plus hydrochlorothiazide.

In a second study, patients with an inadequate response to 3 weeks of eprosartan 600 mg once daily were randomised to eprosartan 600 mg once daily plus placebo or eprosartan 600 mg plus hydrochlorothiazide 12.5 mg once daily. After a further 8 weeks, the mean post-randomization systolic/diastolic blood pressure reduction was 5.8/7.9 mmHg on eprosartan 600 mg plus placebo and 9.2/10.7 mmHg on eprosartan 600 mg plus hydrochlorothiazide 12.5 mg (i.e. 3.4/2.8 mmHg more with the combination; p <0.05). Diastolic blood pressure was normalised (£90 mmHg) in 49% of patients who continued on eprosartan 600 mg once daily, compared with 59% of patients switched to eprosartan 600 mg plus hydrochlorothiazide 12.5 mg. Diastolic blood pressure responded (was normalised or reduced by ³10 mmHg from baseline) in 57% of patients who continued on eprosartan 600 mg once daily, compared with 79% of patients who switched to eprosartan 600 mg plus hydrochlorothiazide 12.5 mg.

No specific data is available on use of Teveten Plus in patients with severe hypertension. However a study using Teveten monotherapy evaluated the efficacy of eprosartan and enalapril in patients with severe systolic hypertension. The reduction of 25.7 mmHg in sitting systolic blood pressure produced by eprosartan once-daily (in titrated doses of 600, 800, 1200 mg, hydrochlorothiazide 25 mg could be added further) was comparable to enalapril once-daily (in titrated doses of 10, 20, 40 mg, hydrochlorothiazide 25 mg could be added further). The percentage of patients receiving hydrochlorothiazide either as study medication or as concomitant medication continued from screening was similar between the two treatment groups.

In long-term open-label studies the antihypertensive effect of eprosartan/ hydrochlorothiazide was maintained for 24 months. The long term effects of eprosartan plus hydrochlorothiazide on mortality and cardiovascular morbidity have not been studied.

Indications

Treatment of hypertension. Treatment should not be initiated with this fixed dose combination.

Contraindications

Teveten Plus is contraindicated in:

  • Patients with known hypersensitivity to any component of the product and sulfonamide derived drugs (e.g. thiazides).
  • Pregnancy and lactation.
  • Severe renal impairment (creatinine clearance <30 mL/min).
  • Haemodynamically significant bilateral renovascular disease or severe stenosis of a solitary functioning kidney.

Precautions

Risk of Renal Impairment

Renal function should be closely monitored in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system, e.g. patients with severe cardiac insufficiency, bilateral renal artery stenosis or renal artery stenosis of a solitary functioning kidney. Patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system have developed oliguria and/or progressive azotaemia and rarely acute renal failure during therapy with ACE inhibitors. Therefore, the possibility of a similar effect with the use of an angiotensin II receptor antagonist cannot be excluded. When eprosartan + hydrochlorothiazide is to be used in patients with renal impairment, renal function should be assessed before starting treatment with eprosartan + hydrochlorothiazide and at intervals during the course of the therapy. If worsening of renal function is observed during therapy, treatment with eprosartan + hydrochlorothiazide should be reassessed (see Contraindications).

Hydrochlorothiazide-associated azotaemia may occur in patients with impaired renal function.

Combination use of angiotensin converting enzyme inhibitors or angiotensin receptor antagonists and anti-inflammatory drugs and thiazide diuretics

The use of an ACE inhibiting drug (ACE inhibitor or angiotensin receptor antagonist) and an anti-inflamatory drug (NSAID or COX-2 inhibitor) and a thiazide diuretic at the same time increases the risk of renal impairment. This includes use in fixed combination products containing more than one class of drug. Combined use of these medications should be accompanied by increased monitoring of serum creatinine, particularly at the institution of the treatment. The combination of drugs from these three classes should be used with caution particularly in elderly patients or those with pre-existing renal impairment.

Other Conditions

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Hepatic Impairment

Hydrochlorothiazide should be used with caution in patients with moderate to severe impairment of hepatic function. There is no clinical experience with Teveten Plus in patients with severe hepatic impairment.

Sodium /Volume Depletion

At the start of therapy, symptomatic hypotension may occur in patients with severe sodium depletion and/or volume depletion (e.g. vigorous diuretic therapy and/or dietary salt restriction, vomiting, diarrhoea and haemodialysis). Sodium and/or volume depletion should be corrected before commencing therapy with Teveten Plus.

Electrolyte Imbalance

Hydrochlorothiazide can cause fluid or electrolyte imbalance (hypokalaemia, hyponatraemia, hypercalcaemia, hypomagnesaemia, and hypochloraemic alkalosis). As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be considered.

Hypokalaemia is mainly associated with higher doses of thiazide diuretic monotherapy. Hyponatraemia and chloride deficit are usually mild and asymptomatic and usually do not require treatment. Calcium excretion may be decreased by thiazide diuretics, causing a slight elevation in serum calcium levels in the absence of a known disorder of calcium metabolism (e.g. hyperthyroidism). Thiazides should be discontinued before carrying out tests for parathyroid function.

Metabolic and Endocrine Effects

Hydrochlorothiazide may impair glucose tolerance, and this may require dosage adjustment of antidiabetic medication. Latent diabetes mellitus may become manifest during therapy with thiazide diuretics.

Minor metabolic or endocrine effects have been reported with low dose (12.5 mg) thiazide diuretics. Monitoring of laboratory parameters may be necessary in patients at risk of metabolic disturbances.

Impairment of Fertility

The effects of eprosartan and hydrochlorothiazide in combination and hydrochlorothiazide monotherapy on fertility have not been investigated. However, administration of eprosartan to male or female rats during gametogenesis at oral doses up to 1000 mg/kg/day did not impair fertility or foetal development (approximately 0.7 times the human exposure at the maximum recommended clinical dose, based on AUC).

Use in Pregnancy

Category D

Teveten Plus is contraindicated in pregnancy.

There is little experience with the use of eprosartan and hydrochlorothiazide in combination during pregnancy. It has been reported that drugs that act directly on the renin-angiotensin system can cause foetal and neonatal morbidity and death. Several dozen cases have been reported in the world literature in patients who were taking ACE-inhibitors. When pregnancy is detected Teveten Plus should be discontinued as soon as possible.

The use of drugs that act directly on the renin-angiotensin system during the second and/or third trimesters of pregnancy, have been associated with foetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure and even death. Oligohydramnios has also been reported, presumably as a result of a decrease in foetal renal function. Oligohydramnios in this setting has been associated with foetal limb contractures, craniofacial deformation and hypoplastic lung development. Prematurity, intrauterine growth retardation and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.

In rare cases, where no alternative treatment can be found, serial ultrasound examinations should be performed to assess the intra-amniotic environment. If oligohydramnios is observed, Teveten Plus should be discontinued unless it is considered lifesaving. Patients and physicians should be aware that oligohydramnios might not appear until after the foetus has sustained irreversible injury. Infants with a history of in utero exposure to an angiotensin II receptor antagonist should be closely observed for hypotension, oliguria and hyperkalaemia.

Intra-uterine exposure to the drug during the first trimester only, does not appear to result in these adverse events. However, mothers whose embryos and foetuses have been exposed to an angiotensin II receptor antagonist during the first trimester should be informed of the potential risks. Women of childbearing age should be warned of the potential hazards to their foetus and asked to report pregnancies to their physician as soon as possible.

Thiazides cross the placental barrier and appear in cord blood.

Studies in pregnant rabbits showed an increased incidence of late resorptions and dead foetuses when eprosartan/hydrochlorothiazide were administered at non- maternotoxic doses of 10/3 mg/kg/day during late gestation. These doses are associated with drug exposure similar to those expected in humans after administration of Teveten Plus.

Eprosartan alone was not teratogenic in rats at oral doses of up to 1000 mg/kg/day (approximately 0.7 times the human exposure at the maximum recommended clinical dose, based on AUC). It was not teratogenic in rabbits at doses up to 30 mg/kg/day (the highest dose tolerated and approximately 9 times the human exposure at the maximum recommended clinical dose, based on AUC), but was maternotoxic from 3 mg/kg/day and caused increased foetal mortality from 10 mg/kg/day (less than human exposure at the maximum recommended clinical dose, based on AUC). The mechanism of the high toxicity in rabbits has not been investigated, but may be related to effects on the renin-angiotensin system in combination with higher exposure levels at low doses.

Use in Lactation

Due to the potential for adverse effects on the infant, women should not breast feed while taking Teveten Plus. Eprosartan is excreted in the milk of lactating rats, however there is no information on excretion of the drug in human breast milk. Hydrochlorothiazide is excreted in human breast milk.

Paediatric Use

As the safety and efficacy in children have not been established, treatment of children is not recommended.

Use in the Elderly

In clinical studies no significant difference was observed in efficacy and safety between older patients (>65 years of age) and younger patients.

Carcinogenicity

The carcinogenic potential of eprosartan and hydrochlorothiazide in combination has not been investigated in animal studies. Studies to investigate the carcinogenic potential of eprosartan indicated no carcinogenicity in rats or mice administered eprosartan orally by gavage for 2 years. The highest doses tested were 600 mg/kg/day in rats and 2000 mg/kg/day in mice. These doses provided systemic exposure to eprosartan, which in rats was less than, and in mice about 3 times more than the exposure expected in human patients receiving the maximum daily dose of 800 mg, based on AUC.

Two year feeding studies in mice and rats with hydrochlorothiazide uncovered no evidence of carcinogenic potential in female mice at doses up to approximately 600 mg/kg/day, or in male and female rats at doses up to approximately 100 mg/kg/day. The studies, however, uncovered equivocal evidence for hepatocarcinogenecity in male mice treated with hydrochlorothiazide at approximately 600 mg/kg/day.

Genotoxicity

The combination of eprosartan and hydrochlorothiazide (600 mg/12.5 mg) did not induce gene mutations (in vitro in bacterial cells). The combination caused chromosomal aberrations when tested in vitro (human lymphocytes) but was negative in an in vivo assay (mouse micronucleus assay).

Eprosartan was not genotoxic in a series of assays for gene mutations and chromosomal damage. Hydrochlorothiazide was not genotoxic in a gene mutation assay in bacterial cells, or in tests for clastogenic activity in vitro and in vivo. However, positive results were obtained in a mammalian cell assay for gene mutation (mouse lymphoma cell assay) and in two other tests (sister chromatid exchange assay in Chinese hamster ovary cells and non-disjunction assay in Aspergillus nidulans)

Interactions with Other Medicines

Eprosartan + Hydrochlorothiazide

Concomitant use of Teveten Plus and other antihypertensives may result in enhanced blood pressure lowering effects.

NSAIDs may attenuate the diuretic and antihypertensive effects of Teveten Plus.

Eprosartan

In vitro human cytochrome P450 enzymes CYP1A, 2A6, 2C9/8, 2C19, 2D6, 2E, and 3A, associated with drug-metabolism, are not inhibited by eprosartan. Ranitidine, ketoconazole and fluconazole have shown no effects on the pharmacokinetics of eprosartan.

Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. While this has not been documented with eprosartan, the possibility of a similar effect cannot be excluded. Diuretic agents reduce renal clearance of lithium and increase the risk of lithium toxicity. Careful monitoring of serum lithium levels is recommended during concomitant use with Teveten Plus.

Hydrochlorothiazide

By lowering serum potassium levels, hydrochlorothiazide can increase the effects and side-effects of digitalis and anti-arrhythmic drugs.

Hydrochlorothiazide increases the risk of hypokalaemia particularly if it is concomitantly administered with drugs associated with potassium loss, such as kaliuretic diuretics, laxatives, corticosteroids and ACTH.

Based on the reported experience with the use of drugs which affect the renin- angiotensin system, potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with TevetenPlus.

Dosage adjustment of anti-diabetic drugs may be required (see Precautions).

Absorption of hydrochlorothiazide is reduced by anionic exchange resins such as cholestyramine or colestipol.

Hydrochlorothiazide may increase the effects of non-depolarizing (tubocurarin-type) skeletal muscle relaxants.

Effects on Ability to Drive and use Machines

Based on its pharmacodynamic properties, Teveten Plus is unlikely to affect the ability to drive or operate machinery. However, it should be taken into account that occasionally dizziness or fatigue may occur during treatment of hypertension.

Adverse Effects

Eprosartan in combination with hydrochlorothiazide at doses equal to or greater than those provided by Teveten Plus has been evaluated for safety in more than 1600 subjects worldwide, including more than 500 patients treated for 1 year or longer. The incidence of adverse events was unrelated to age, gender or race. Most adverse events were generally mild to moderate in severity and transient by nature and similar to those seen with the individual components taken separately.

In controlled clinical trials involving 782 patients (8 weeks duration), withdrawals due to treatment related adverse events were, 2.6% for eprosartan/hydrochlorothiazide, 2.5% for placebo, 1.8% for eprosartan and 5.1% for hydrochlorothiazide

Table 1 lists adverse events that occurred at an incidence of 1% or more among eprosartan + hydrochlorothiazide(HCTZ)-treated patients who participated in a placebo-controlled trial of 8 weeks duration, using doses of 600/12.5 mg once-daily.

Table 1: Adverse Events Reported by ≥1% of Patients Receiving Teveten Plus in a Placebo-Controlled Clinical Study
  Frequency (% of patients)
Event Eprosartan
+ HCTZ
(n=116)
Eprosartan

(n=118)
HCTZ

(n=117)
Placebo

(n=122)
Body as a whole        
Fatigue 2.6 1.7 0.9 0.8
Insomnia 1.7 0.8 1.7 0.0
Oedema dependent 2.8 1.8 0.0 0.9
Cardiovascular        
Palpitations 1.7 0.8 1.7 2.5
Heart disorder 2.6 0.8 0.0 0.8
Musculoskeletal        
Back pain 2.6 5.1 1.7 3.3
Arthrosis 1.7 0.8 0.0 0.8
Arthralgia 1.7 0.0 0.0 0.8
Nervous system        
Headache 5.1 11.0 9.4 10.6
Dizziness 5.2 3.4 1.7 1.6
Neuralgia 2.6 1.7 0.0 1.6
Paraesthesia 1.7 1.7 0.0 0.8
Nervousness 1.7 0.8 0.0 1.6
Respiratory        
Bronchitis 2.6 2.5 2.6 0.0
Respiratory
disorder
1.7 0.0 1.7 1.6
Rhinitis 1.7 0.0 0.0 0.0
Urogenital        
Albuminuria 3.4 1.7 1.7 1.6
Pyuria 2.6 2.5 1.7 0.8
Haematuria 1.7 2.5 1.7 0.8

Adverse events that occurred in more than two (2) hypertensive patients when taking Teveten Plus during controlled and uncontrolled clinical trials and that were not reported in Table 1 are listed below. Events are listed within body systems and categorised by frequency according to the following definitions:

Common (frequency ≥1 and <10%)

Uncommon (frequency ≥0.1% and < 1%)

Rare (frequency ≥0.01% and < 0.1%)

Body as a whole: Common: asthenia, injury, pain
Uncommon:
fever, syncope, allergy
Cardiovascular Uncommon: hypotension
Nervous system Uncommon: hypaesthesia, vertigo
Gastro intestinal Common: abdominal pain, diarrhoea, nausea, gastroenteritis
Uncommon
: dyspepsia
Liver and biliary system Uncommon: SGPT increased
Metabolic and nutritional Common: hyperglycaemia, hypokalaemia
Muscular system Uncommon: bursitis, myalgia
Psychiatric Uncommon: anxiety, depression, insomnia
Respiratory Uncommon: coughing, dyspnoea, epistaxis, pharyngitis, sinusitis, upper respiratory tract infection
Skin and appendages Uncommon: rash
Urinary system Common: urinary tract infection, cystitis

Laboratory Test Findings: Treatment with Teveten Plus for up to 2 years was associated with small increases in serum uric acid, plasma glucose and triglycerides. These were not clinically significant.

Eprosartan monotherapy: Adverse events with eprosartan have usually been mild and transient in nature and have only required discontinuation of therapy in 4.1% of patients in placebo-controlled studies (6.5% for placebo). The adverse events reported are similar to those reported for the combination product.

Post Marketing Reports

In addition to those adverse events reported during clinical trials, the following side effects have been reported spontaneously during postmarketing use of eprosartan.

As with other angiotensin II receptor antagonists, very rare cases of facial swelling and/or angioedema have been reported. Reports of hypotension, including orthostatic hypotension have been uncommon. Rare cases of skin reactions (rash, pruritus, urticaria) have been reported. Headache, dizziness, asthenia, anxiety, insomnia, nervousness, paraesthesia, somnolence and vertigo have been reported rarely.

The following adverse events have been reported spontaneously during postmarketing use of eprosartan.

Renal and Urinary Disorders Impaired renal function including renal failure in patients at risk (e.g. renal artery stenosis)

Hydrochlorothiazide monotherapy: The following reactions have been reported in addition to those reported for the combination therapy:

Gastrointestinal disorders anorexia, stomach discomfort, vomiting, cramps, constipation, pancreatitis, sialoadenitis
Immune system disorders Anaphylactic reactions
Nervous system disorders Restlessness, xanthopsia
Vascular disorders orthostatic hypotension, vasculitis
Blood and lymphatic system disorders Leukopenia, agranulocytosis, thrombocytopenia, aplastic anaemia, haemolytic anaemia
Metabolism and nutrition disorders hyperuricaemia, gout, hyponatraemia, hypochloraemia, hypercalcaemia, hypomagnesaemia, hyper-cholesterolaemia, hypertriglyceridaemia
Psychiatric disorders Libido disorder
Hepatobiliary disorders Jaundice (intrahepatic cholestatic jaundice),
Renal and urinary disorders Renal impairment, interstitial nephritis, renal failure
Respiratory, thoracic and mediastinal disorders Pneumonitis, pulmonary oedema
Musculoskeletal and connective tissue disorders Systemic lupus erythematosus, muscle spasms
Skin and subcutaneous tissue disorders Photosensitivity reaction, toxic epidermal necrolysis, purpura, urticaria
Reproductive system and breast disorders Sexual dysfunction
General disorders and administration site conditions asthenia, pyrexia

The following adverse events have been reported spontaneously during postmarketing use of eprosartan + hydrochlorothiazide.

Psychiatric disorders Depression, anxiety, insomnia, nervousness, restlessness

Dosage and Administration

Teveten Plus should not be initiated as first line therapy.

Teveten Plus may be used for patients whose blood pressure is not adequately controlled on either hydrochlorothiazide or eprosartan alone. Most of the antihypertensive effect with eprosartan is usually attained within four weeks of initiation of treatment. Therefore, Teveten Plus should only be initiated after an adequate trial period of monotherapy with eprosartan or hydrochlorothiazide, preferably lasting 4-6 weeks.

The recommended dose of Teveten Plus is one tablet daily. Teveten Plus can be taken with or without food.

Discontinuation of treatment does not lead to rapid rebound increase in blood pressure.

Patients Who are Salt or Volume Depleted or on Existing Diuretic Therapy

In patients who are salt or volume depleted, for example due to diuretic therapy, the condition should be corrected before starting Teveten Plus. Patients on diuretic therapy should cease the diuretic 2-3 days before starting Teveten Plus.

Elderly, Hepatically or Renally Impaired Patients

Initial dose adjustment is generally not required in the elderly, in patients with mild to moderate hepatic impairment or in patients with mild to moderate renal impairment (creatinine clearance ≥30 mL/min). Teveten Plus is not recommended in patients with severe hepatic impairment or severe renal impairment (creatinine clearance <30 mL/min).

Overdosage

There is no clinical experience with overdose of Teveten Plus. Overdose may be expected to cause hypotension, dehydration and electrolyte abnormalities (including hypo or hyperkalaemia, hypochloraemia and hyponatraemia). These may be associated with cardiac arrhythmias, somnolence or nausea. Treatment should be symptomatic and supportive. If hypotensive, the patient should be placed in a supine position. Electrolyte and volume replacements should be given as required and the patient should be monitored for electrolyte disturbances and cardiac arrhythmias. Activated charcoal may be administered. Eprosartan is not removed by haemodialysis. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.

Contact the Poisons Information Centre on 13 11 26 for management of overdose.

Presentation and Storage Conditions

Butterscotch coloured, capsule shaped, film coated tablets, marked “5147” on one side. Blister packs of 7, 14*, 28 or 56* tablets per carton.

*Not marketed in Australia

Teveten Plus tablets should be stored at or below 25˚C.

Poison Schedule of the Medicine

Schedule 4 – Prescription Only Medicine.

Name and Address of the Sponsor

Abbott Australasia Pty Ltd

32-34 Lord Street

Botany NSW 2019

Australia

Date of Approval

Date of TGA approval: 28 March 2002

Date of most recent amendment: 14 June 2012